Eli Lilly’s one-time blockbuster hopeful baricitinib $LLY is back and on track and ready to run a gamut of outside experts at the FDA.
TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the completion of an oversubscribed Series B financing of $125 million.
Researchers have developed what they have dubbed a ‘brain stethoscope’, a device capable of turning EEG brain wave data into sound. The device is able to detect epileptic seizures that do not result in convulsions.
Patient engagement platform Medical Mindset just landed $1 million in investment capital. The company's platform allows patients to build a HIPAA-compliant health profile, which they can use to check into an appointment by swiping their smartphone.
GlaxoSmithKline's new CEO Emma Walmsley isn’t the only one shaking things up at the top of the British drugmaker.
The EU medicines regulator has started its review of Astellas and Pfizer’s prostate cancer drug Xtandi in what looks likely to become a hotly contested indication - non-metastatic castration-resistant prostate cancer (nmCRPC).
Having an accurate record of food and alcohol intake is important for managing a number of diseases including diabetes, various cardiovascular conditions, and alcoholism. Currently, not much practical technology is available to do this aside from smartphone apps, and apps tend to be tedious and require constant vigilance of making sure to input all the data.
In collaboration with Google, Facebook, Yahoo and LinkedIn, Ddu recently launched their priority products rally to help users on the platform capture business opportunities, hosting an online medical device product fair to get mass exposure for users' quality products.
Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced a global collaboration with Celgene Corporation (CELG) through a subsidiary, to develop new therapies for a broad range of neurodegenerative diseases.
Artificial intelligence company twoXAR—a specialist in separating signals from noise in data-rich drug discovery projects—has raised $10 million in a first-round financing led by SoftBank Ventures.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.